Skin Cancer

A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.

Cancer Network spoke with Anna Pavlick, MD, of NYU Langone Health, on the results of a phase II study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared with Montanide.

The results of the phase II trial examining combination immunotherapy were presented during the ASCO 2019 meeting.

Findings from a pooled analysis of two phase III trials, COMBI-d and COMBI-v, centered on outcomes with first-line dabrafenib plus trametinib vs either agent alone.

Data from the largest randomized neoadjuvant trial in resectable stage IIIB–IVM1a melanoma to date were presented at ASCO 2019.

The investigators looked at whether whole-brain radiotherapy improved outcomes in patients with melanoma brain metastasis.

A recent study evaluated whether longstanding assumptions that thin nodular melanomas are less aggressive than thicker ones are accurate.

Researchers studied whether risk factors differ for early-stage melanoma metastasis via the lymphatic system and the bloodstream.

Study authors evaluated clinically relevant differences in nonwhite vs white pediatric patients with melanoma and atypical melanocytic neoplasms.

The American Cancer Society's Cancer Facts & Figures 2019 report summarized the rate of melanoma over the past 30 years, mortality, and incidence based on sex and ethnicity.

The study authors evaluated the disease-free survival rate among patients with high-risk primary melanoma and the role of routine sentinel lymph node biopsy.

A new study reported that elderly patients experience a different extent of metastatic disease than do adults diagnosed at younger ages.

The authors discuss the potential use and limitations of immunotherapy among patients with squamous cell cancer, basal cell carcinoma, and other skin cancers.

Researchers evaluated the response of patients with BCC to fractionated photodynamic therapy at 30 days after treatment.

Researchers evaluated whether treatment with calcipotriol plus 5-fluorouracil aided in reducing the risk of squamous cell carcinoma.

The association between the presence of several viruses and non-melanoma skin cancer was investigated in a recent study.

A review published in Experimental Dermatology examined the safety and efficacy of nicotinamide in reducing non-melanoma skin cancers.

Survival rates in patients with cSCC receiving high-dose chemoradiotherapy vs conventional radical surgery were compared.

The CheckMate 511 phase IIIb/IV trial investigated raising the nivolumab dose to 3 mg/kg and lowering the ipilimumab dose to 1 mg/kg.

A recent review article highlighted developments in the treatment of non-melanoma skin cancers, from new chemoprevention agents to telemedicine.

A new meta-analysis offers compelling evidence on the causal relationship between indoor tanning and skin cancer risk.

The findings of a systematic review may help standardize reflectance confocal microscopy terminology, which is used to describe non-melanocytic lesions.

Researchers studied whether the mechanistic target of mTORC2 directs UVB–induced apoptosis by regulating the expression of NOXA downstream of FOXO3a.

A new study in Cancer Research evaluated the function of TRIM29 in regulating keratin distribution and migration/invasion of SCC.

Researchers evaluated the efficacy of 5-florouracil vs imiquimod in preventing site-specific keratinocyte carcinoma.

A recent study examined the literature on whether immune checkpoint molecules improve overall survival in oral squamous cell carcinoma.

Investigators shared results of an interim analysis evaluating antitumor activity and safety in patients with mMCC receiving avelumab monotherapy.

Cemiplimab (Libtayo), approved for advanced cutaneous squamous cell carcinoma, is intended for those not eligible for curative surgery or radiation.

The percentage of patients with pediatric melanoma is 6-fold to the 28-fold higher when compared with the general population of patients with melanoma.